non-clinical trial institute
Scope
Date
~
-
Mergers & Acquisitions
HYBE kicks off campaign to win over SM shareholders
Bang Si-hyuk, founder and chairman of the BTS label HYBE Co., has kicked off his campaign to gather support from institutional investors to take con...
Mar 09, 2023 (Gmt+09:00)
-
Bio & Pharma
GC Biopharma to develop mRNA flu vaccine with Canadian pharma
South Korea's GC Biopharma Corp. announced on Thursday that it will start developing a flu vaccine based on messenger ribonucleic acid (mRNA).The dr...
Mar 09, 2023 (Gmt+09:00)
-
Upcoming IPOs
Korea’s sole foreign clinic operator CHA Healthcare to go public in 2025
CHA Healthcare Co. operating nearly 90 hospitals and infertility treatment centers across the world, is set to pave the way for South Koreans' inves...
Mar 08, 2023 (Gmt+09:00)
-
Robotics
Korea's SK Telecom jointly develops AI patrol robots
SK Telecom Co., along with its partner firms, will develop artificial intelligence (AI) robots that will replace security guards patrolling around s...
Mar 07, 2023 (Gmt+09:00)
-
Bio & Pharma
Phase 3 clinical plan for SK Bioscience's booster shot approved in Colombia
SK Bioscience Co., a leading South Korean vaccine and biotech company, announced on Monday that its phase 3 clinical trial plan for a heterogeneous ...
Mar 07, 2023 (Gmt+09:00)
-
Bio & Pharma
Korea's ST Pharm completes new R&D hub for gene therapy
ST Pharm Co., a South Korean drug raw material-producing subsidiary of Dong-A Socio Holdings, said on Friday that it has finished building an R&...
Mar 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong Pharma's Fexuclue safe to use with aspirin: Clinical trials
Daewoong Pharmaceutical Co., a leading South Korean pharmaceutical company, has announced the successful completion of phase 1 clinical trials for...
Feb 28, 2023 (Gmt+09:00)
-
Bio & Pharma
SillaJen starts US trial of anti-cancer drug from Basilea
SillaJen Inc. said on Monday it has enrolled the first patient in a US phase 1 trial of an anti-cancer drug BAL0891 licensed from Swiss drugmaker Ba...
Feb 27, 2023 (Gmt+09:00)
-
Bio & Pharma
Jetema applies to test its botulinum toxin in US from July
South Korea's bio-esthetic pharmaceutical company Jetema Co. will hold clinical trials in the US to advance to the American market, the world's bigg...
Feb 27, 2023 (Gmt+09:00)
-
Hydrogen economy
Hyundai Heavy to develop core technology for seawater electrolysis system
Hyundai Heavy Industries Co. signed a business agreement for jointly developing seawater electrolysis system core technology at the Korea Institute ...
Feb 22, 2023 (Gmt+09:00)
-
Private equity
Korea's NPS, KTCU likely to invest in CVC's ninth buyout fund
South Korea’s key institutional investors are highly likely to invest via European private equity giant CVC Capital Partners’ ninth buyo...
Feb 20, 2023 (Gmt+09:00)
-
Economy
Korean jobs up by 22-month low of 411,000 in Jan, with signs of cooling
South Korea added the smallest number of payrolls in nearly two years in January, with mainly part-time jobs taken by people in their 60s and older,...
Feb 15, 2023 (Gmt+09:00)
-
Bio & Pharma
LG Chem builds S.Korea's first plant for clinical trials
LG Chem Ltd. has built South Korea’s first pharmaceutical plant dedicated to clinical trials, which the company expects to speed up its medici...
Feb 14, 2023 (Gmt+09:00)
-
Cloud computing
Hancom goes global with SDK, SaaS products
South Korea’s homegrown office suite developer Hancom Inc. will seek to boost its brand awareness in the global B2B software market with softw...
Feb 10, 2023 (Gmt+09:00)
-
IPOs
Oasis IPO draws tepid interest from institutional investors
South Korean grocery delivery platform Oasis Corp. saw lukewarm interest from domestic institutional investors during the Feb. 7-8 bookbuilding for ...
Feb 09, 2023 (Gmt+09:00)
-
Banking & Finance
Kakao Bank announces record-high performance in 2022
South Korea's KakaoBank Corp. on Wednesday said its net profit last year reached a record-high 263.1 billion won ($208.6 million), up 28.9% from 202...
Feb 09, 2023 (Gmt+09:00)
-
Bio & Pharma
Prestige Bio's Herceptin biosimilar proves equivalence in clinical trials
Prestige Biopharma, a South Korean biopharmaceutical developer, said on Tuesday that the final analysis of phase 3 clinical trial on the anti-cancer...
Feb 08, 2023 (Gmt+09:00)
-
Foreign exchange
S.Korea to allow offshore investors to directly trade won
South Korea is set to allow offshore investors to directly trade the won and extend the operating hours of the local currency market from July next ...
Feb 07, 2023 (Gmt+09:00)
-
Sovereign bonds
S.Korean institutional investors inject more capital in MMFs
South Korean institutional investors, such as pension funds, mutual aids and corporates, are rushing to money market funds (MMFs) for short-term pro...
Feb 06, 2023 (Gmt+09:00)
-
Banking & Finance
Industrial Bank of Korea goes all in with Eastern Europe push
Industrial Bank of Korea (IBK) will open an office in Poland in the first half of this year, with analysts saying the bank's president Kim Seong-tae...
Feb 06, 2023 (Gmt+09:00)
-
Tech, Media & Telecom
S.Korea's NIA to extend IT cooperation project with Kazakhstan
South Korea's state-run research institute National Information Society Agency (NIA) said on Friday that it had signed an agreement with Kazakhstan'...
Feb 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Daewoong Pharma's botulinum toxin Nabota proves long-lasting effect
Daewoong Pharmaceutical said on Friday that a high-dose administration of botulinum toxin Nabota (US brand name: Jeuveau) to patients with frown wri...
Feb 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Prestige Biopharma submits clinical trial plan in Australia
Prestige Biopharma, a Singapore-based biopharmaceutical company with operations in South Korea and the US, has applied to the Australian clini...
Feb 03, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Bioscience's SKYCellflu approved by Chilean health authority
SK Bioscience Co., a bio and pharmaceutical affiliate of South Korea's SK Group, announced on Thursday that its world-first cell culture-based quadr...
Feb 02, 2023 (Gmt+09:00)
-
Bio & Pharma
GC Cell's AB-101 NK therapy achieves FDA fast-track status
South Korea's bio firm GC Cell announced on Wednesday that its US affiliate Artiva Biotherapeutics has received fast-track designation from the US F...
Feb 02, 2023 (Gmt+09:00)
-
Bio & Pharma
Inventage Lab launches clinical trials for addiction treatment in Australia
South Korea's Inventage Lab, a developer of a drug delivery system platform, on Wednesday said it received approval from the Human Research Ethics C...
Jan 26, 2023 (Gmt+09:00)
-
Artificial intelligence
LIG Nex1 opens AI research lab jointly with Korea Robot Institute
LIG Nex1 Co. said on Wednesday that it held an "AI Co-Lab" opening ceremony at the Seoul office of the Korea Institute of Robot and Convergence (KIR...
Jan 20, 2023 (Gmt+09:00)
-
Bio & Pharma
NGeneBio's diagnostic products start to be used in clinical tests in Vietnam
South Korea's medical diagnostics company NGeneBio Co. said on Wednesday that it is expanding its business in the Southeast Asian precision diagnost...
Jan 19, 2023 (Gmt+09:00)
-
Automobiles
Kakao Mobility launches future mobility hardware think tank
South Korea's Kakao Mobility has launched a think tank to study next-generation mobility hardware under the company's bid to lead overall innovation...
Jan 17, 2023 (Gmt+09:00)
-
Bio & Pharma
Medipost completes first dose of Cartistem in phase 3 clinical trials in Japan
South Korea's stem cell research company Medipost Co. said on Monday that it has completed the administration of Cartistem, a stem cell treatment fo...
Jan 17, 2023 (Gmt+09:00)
Latest News
- 1 Korea's Hana Bank to promote foreigners as managers in overseas units
- 2 Samsung to unveil 400-layer bonding vertical NAND for AI servers by 2026
- 3 Korean LPs sharpen eyes on GPs' post-investment management
- 4 LG Energy Q3 profit more than doubles on higher sales
- 5 Kakao Mobility to launch outdoor robot delivery